FDA’s top cancer drug regulator played key role in rejection of Replimune therapy, officials say

Taking stock of the drug industry, from the lab to the medicine chest

August 4, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

FDA STAT+ | FDA's top cancer drug regulator played key role in rejection of Replimune therapy, officials say Agency officials said Vinay Prasad, who was criticized before his ouster for taking a hard line in reviews, did not have substantive role in debate. By Adam Feuerstein The murkiness of drug companies' price transparency reports The reports disclose no pricing information about specific drugs, manipulating the reality over how much people spend on prescription drugs. By Bob Herman STAT+ | Uncertainty clouds the San Diego biotech hub, with jobs and capital scarce San Diego's biotech hub faces rising layoffs, vacant lab space, and dwindling funding, but local leaders say region is poised for a rebound By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser